Business
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts. NKGen’s Cha
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech, Inc.","displaySize":"","headline":null,"caption":"NKGen Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ui_febjO_II.F5hi8oLzdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510","width":300,"height":88}},"lazy":false},{"type":"text","content":"SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.","length":488,"tagName":"p"},{"type":"text","content":"NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (“FTD”). The presentation will include an overview of the Company's expanding mechanistic dataset, including evidence that troculeucel selectively targets autoreactive T cells and may modulate key neuroinflammatory pathways implicated in disease progression.","length":491,"tagName":"p"},{"type":"text","content":"Dr. Song will also review clinical observations from early-stage studies, including encouraging biomarker trends and reductions in neuroinflammatory signals measured in cerebrospinal fluid. These data build on previously reported preclinical and clinical findings and further support troculeucel’s potential as a differentiated, cell-based approach to treating neurodegenerative disorders with high unmet medical need.","length":418,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"max-width:10%;width:100.048%;min-width:10%;","val":[{"type":"text","content":"NKGen Presentation Details:","length":27,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:12.2369%;","val":[{"type":"text","content":"Title:","length":6...